None

NICE flip-flops on Esbriet and Revolade

NICE, the UK's health technology appraisal body, has made a U-turn on previous decisions and is now recommending both Intermune's Esbriet (pirfenidone) and GlaxoSmithKline's Revolade (eltrombopag)....

InterMune: Weak Esbriet Sales But In-Line Pricing

BRISBANE, Calif. (TheStreet) -- InterMune reported weak sales of its lung disease therapy Esbriet for the second quarter but the company did manage to negotiate final pricing with German authorities t...

NICE recommends against InterMune's Esbriet for IPF

The U.K.'s NICE issued draft guidance recommending against Esbriet pirfenidone from InterMune Inc. (NASDAQ:ITMN) to treat mild to moderate idiopathic pulmonary fibrosis (IPF). The committee said Esbri...

InterMune falls as Esbriet revenues miss Street

Shares of InterMune Inc. (NASDAQ:ITMN) fell $1.81 (15%) to $9.90 on Monday after idiopathic pulmonary fibrosis (IPF) drug Esbriet pirfenidone recorded 2Q12 revenue of $5.5 million, missing the Street'...

U.K.’s NICE Backs Esbriet, Xolair And Orencia After Getting Price Discounts

In a day of three positive recommendations helped by discounts, Bristol’s Orencia for rheumatoid arthritis, Novartis’ Xolair for Asthma and InterMune’s Esbriet for IPF finally make it onto the U...

NICE 'yes' to Esbriet, Xolair and Orencia

In its latest round of decisions, NICE England's health technology appraisal institute, has recommended Intermune's Esbriet (pirfenidone) for certain idiopathic pulmonary fibrosis patients, Novart...

InterMune to pay flat-rate EU Esbriet royalty to settle Shionogi dispute

Shionogi took legal action in the US against InterMune in July last year, claiming that the US firm had failed to pay due royalties on its sales of the idiopathic pulmonary fibrosis drug Esbriet (pi...

InterMune's pulmonary fibrosis drug Esbriet wins Canadian approval

Health Canada approved InterMune's Esbriet, or pirfenidone, as a therapy for idiopathic pulmonary fibrosis.  -More- 

None